top of page

First-in-Class Therapeutics

for CMT1A & Neuropathies

PRECISION™ Neurotherapeutics

icons8-neuron-64 (2).png

CELLTIUM pioneers precision neurotechnology to deliver First-in-Class, disease-modifying therapies for CMT1A and intractable neurological disorders.

icons8-celltium-96.png

CELLTIUM's proprietary PRECISION™ HCS platform is built on disease-relevant nervous system models with the integration of machine learning algorithms and fine-tuned automation.

icons8-people-96.png

CELLTIUM is seeking exceptional talent. Unleash your vision and shape the future of breakthrough medicines at CELLTIUM.

CELLTIUM is collaborating with leading investors and strategic partners to further biotech innovations for healthier humanity.

DAEKYO Daekyo Investment.png
SL Invenuki.png
Korea University Technology Holding Nuki.png
JB Lucky.png
Korea Venture Investment Lucky.png
Shinhan Lucky.png

© 2026 CELLTIUM

bottom of page